Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Accrued expenses and other current liabilities (Tables)

3 Months Ended

Mar. 31, 2020

Accrued expenses and other current liabilities consisted of the following (in thousands):


	March 31,		December 31,
	2020		2019
Accrued clinical and development expenditure	$	9,491	$	8,782
Accrued employee expenses		3,814		6,863
Other accrued expenditure		2,562		2,662
Accrued purchase commitments		2,500		5,000
Other		135		56
	$	18,502	$	23,363